ZA200700865B - Solid forms of the magnesium salt of (S)-omeprazole and processes for their preparation - Google Patents

Solid forms of the magnesium salt of (S)-omeprazole and processes for their preparation

Info

Publication number
ZA200700865B
ZA200700865B ZA200700865A ZA200700865A ZA200700865B ZA 200700865 B ZA200700865 B ZA 200700865B ZA 200700865 A ZA200700865 A ZA 200700865A ZA 200700865 A ZA200700865 A ZA 200700865A ZA 200700865 B ZA200700865 B ZA 200700865B
Authority
ZA
South Africa
Prior art keywords
omeprazole
magnesium salt
solid forms
preparation
solvent
Prior art date
Application number
ZA200700865A
Other languages
English (en)
Inventor
Berenguer Maimo Ramon
Coppi Laura
Gasanz Guillen Yolanda
Medrano Ruperez Jorge
Original Assignee
Esteve Quimica Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Quimica Sa filed Critical Esteve Quimica Sa
Publication of ZA200700865B publication Critical patent/ZA200700865B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200700865A 2004-07-02 2005-06-29 Solid forms of the magnesium salt of (S)-omeprazole and processes for their preparation ZA200700865B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200401729A ES2246149B1 (es) 2004-07-02 2004-07-02 Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.

Publications (1)

Publication Number Publication Date
ZA200700865B true ZA200700865B (en) 2009-09-30

Family

ID=34972307

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200700865A ZA200700865B (en) 2004-07-02 2005-06-29 Solid forms of the magnesium salt of (S)-omeprazole and processes for their preparation

Country Status (19)

Country Link
US (1) US7902370B2 (de)
EP (1) EP1765807B1 (de)
JP (2) JP5575366B2 (de)
KR (1) KR101290035B1 (de)
CN (1) CN1976923B (de)
AT (1) ATE425975T1 (de)
AU (1) AU2005259205B2 (de)
CA (1) CA2570559C (de)
CY (1) CY1109048T1 (de)
DE (1) DE602005013382D1 (de)
DK (1) DK1765807T3 (de)
ES (2) ES2246149B1 (de)
HR (1) HRP20090211T1 (de)
MX (1) MXPA06014736A (de)
NO (1) NO20070635L (de)
NZ (1) NZ552458A (de)
PT (1) PT1765807E (de)
WO (1) WO2006003163A1 (de)
ZA (1) ZA200700865B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
FR2920428B1 (fr) * 2007-08-29 2012-06-15 Univ Rouen Procede de dedoublement de sels de l'omeprazole
EP2147918A1 (de) * 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Verfahren zur Herstellung von S-Omeprazol-Magnesium in einer stabilen Form
CN103044400A (zh) * 2012-12-21 2013-04-17 北京华禧联合科技发展有限公司 埃索美拉唑镁盐及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
ATE414509T1 (de) * 1994-07-08 2008-12-15 Astrazeneca Ab Aus vielen einzeleinheiten zusammengesetzte tablettierte dosisform
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
DE60023154T2 (de) * 1999-08-26 2006-06-22 Aaipharma Inc. Alkoxy-substituierte benzimidazolverbindungen , diese enthaltende arzneimittel und ihre verwendung
US6326384B1 (en) * 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6312712B1 (en) * 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
EP1706397A4 (de) * 2000-05-15 2007-08-01 Ranbaxy Lab Ltd Neue amorphe form von omeprazolsalzen
CA2386716C (en) * 2002-05-17 2012-07-24 Bernard Charles Sherman Magnesium salt of s-omeprazole
WO2002012225A1 (fr) * 2000-08-04 2002-02-14 Takeda Chemical Industries, Ltd. Sels de composé à base de benzimidazole et leurs applications
SI20875A (sl) * 2001-04-25 2002-10-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristalna oblika omeprazola
WO2003089408A2 (en) * 2002-04-22 2003-10-30 Sun Pharmaceutical Industries Limited Optically active substituted pyridinylmethyl-sulphinyl-benzimidazole and salts
US6894066B2 (en) * 2002-05-09 2005-05-17 Bernard Charles Sherman Magnesium salt of S-omeprazole
US7612098B2 (en) * 2002-08-30 2009-11-03 Dr. Reddy's Laboratories Limited Amorphous hydrous esomeprazole magnesium
EP1556043A1 (de) 2002-10-22 2005-07-27 Ranbaxy Laboratories, Ltd. Amorphe form von esomeprazol-magnesiumsalz
US20040242642A1 (en) * 2002-11-18 2004-12-02 Dr. Reddy's Laboratories Limited Crystalline esomeprazole compounds and process for the preparation thereof
AU2003238671A1 (en) * 2003-04-10 2004-11-01 Hetero Drugs Limitd Novel crystalline forms of s-omeprazole magnesium
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.

Also Published As

Publication number Publication date
NO20070635L (no) 2007-03-20
ES2246149B1 (es) 2007-06-01
KR101290035B1 (ko) 2013-07-30
CA2570559A1 (en) 2006-01-12
US20070249684A1 (en) 2007-10-25
US7902370B2 (en) 2011-03-08
MXPA06014736A (es) 2007-06-25
ES2323319T3 (es) 2009-07-13
PT1765807E (pt) 2009-04-13
HRP20090211T1 (en) 2009-05-31
NZ552458A (en) 2010-07-30
JP5575366B2 (ja) 2014-08-20
EP1765807A1 (de) 2007-03-28
CA2570559C (en) 2012-08-28
AU2005259205A1 (en) 2006-01-12
DE602005013382D1 (de) 2009-04-30
JP2014169302A (ja) 2014-09-18
JP2008505160A (ja) 2008-02-21
AU2005259205B2 (en) 2011-01-27
WO2006003163A1 (en) 2006-01-12
CN1976923B (zh) 2011-08-24
DK1765807T3 (da) 2009-06-08
ATE425975T1 (de) 2009-04-15
KR20070031992A (ko) 2007-03-20
CN1976923A (zh) 2007-06-06
ES2246149A1 (es) 2006-02-01
EP1765807B1 (de) 2009-03-18
CY1109048T1 (de) 2014-07-02

Similar Documents

Publication Publication Date Title
CN104470919B (zh) 作为pad4抑制剂的2-(氮杂吲哚-2-基)苯并咪唑
DK1073694T3 (da) Trans-xanthophyllesterkoncentrater med forøget renhed og fremgangsmåder til fremstilling af samme
UA109774C2 (uk) Кристалічні форми саксагліптину та процес його одержання (варіанти)
HU229514B1 (en) 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
TW200738160A (en) Production process of purified green tea extract
ZA200600012B (en) Process for preparing maltitol enriched products
Chavan et al. Efficient and mild method for preparation of allylic amines from aziridine-2-alcohols using PPh3/I2/imidazole
ZA200700865B (en) Solid forms of the magnesium salt of (S)-omeprazole and processes for their preparation
ATE508136T1 (de) Verbessertes verfahren zur herstellung von chlorierter saccharose
WO2007054964A3 (en) Process for the preparation of letrozole
AU2003219729A1 (en) Process for the prepatation of ascorbic acid
DE50104094D1 (de) Verfahren zur Herstellung von reinem Triethylendiamin (TEDA)
DE502005004950D1 (de) Verfahren zur herstellung einer lösung von reinem triethylendiamin (teda)
CN107474021B (zh) 噁二嗪衍生物及其制备方法和应用
UA95781C2 (en) Process of preparing bromopicrin
Austad et al. Development of a multi kilogram-scale, tandem cyclopropanation ring-expansion reaction en route to hedgehog antagonist IPI-926
WO2007092705A3 (en) Process for preparing gemcitabine and associated intermediates
DE69838686T2 (de) Tripeptidylpeptidaseinhibitoren
WO2007070238A3 (en) Processes for the preparation of modafinil and analogs thereof
CN103619815A (zh) 脯氨酸化合物的制造方法
ES2439322T3 (es) Derivados de amino alcohol y sus actividades terapéuticas
CN111909081B (zh) 一种吡丙醚原药的纯化方法及由其得到的产品及用途
CN103896819B (zh) 一种(s)-1-氯乙酰基吡咯烷-2-甲酰胺的制备方法
Misra et al. Resolution, absolute configuration and antifilarial activity of coumarinyl amino alcohols
Sun et al. Enantioselective synthesis of the side-chain acid of homoharringtonine and harringtonine from the same γ-butyrolactone intermediate